Form 4 for TMO Thermo Fisher Scientific
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-23 · accession 0001127602-24-006839 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-26 | 2024-02-23 | TMO | CASPER MARC N | COB, CEO, Dir | F - Tax | $564.71 | -1,884 | 128.5K | -1% | -$1.06M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-23 | F | D | 1,884.38 | $564.71 | 128,485.38 | D | — | — | (F1) Reflects a downward adjustment of 805 shares of a performance-based restricted stock unit award granted on February 23, 2021. On February 23, 2022, the reporting person reported the acquisition of the performance-based restricted stock unit award. One-third of the shares vested on February 23, 2022, one-third of the shares vested on February 23, 2023, and the remaining one-third vested on February 23, 2024, subject to adjustment based on the Company's relative total shareholder return ("TSR") over the measurement period starting on January 1, 2021, through to December 31, 2023. As a result of the Company's relative TSR, the third tranche was adjusted downward by 15%. As such, the reporting person received 805 less shares than the amount initially reported. |